BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 8634146)

  • 1. Transcriptional repression of human insulin-like growth factor-II P4 promoter by Wilms' tumor suppressor WT1.
    Lee YI; Kim SJ
    DNA Cell Biol; 1996 Feb; 15(2):99-104. PubMed ID: 8634146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product.
    Dey BR; Sukhatme VP; Roberts AB; Sporn MB; Rauscher FJ; Kim SJ
    Mol Endocrinol; 1994 May; 8(5):595-602. PubMed ID: 8058069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells.
    Nichols KE; Re GG; Yan YX; Garvin AJ; Haber DA
    Cancer Res; 1995 Oct; 55(20):4540-3. PubMed ID: 7553624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repression of promoters for the mouse insulin-like growth factor II-encoding gene (Igf-2) by products of the Wilms' tumour suppressor gene wt1.
    Ward A; Pooler JA; Miyagawa K; Duarte A; Hastie ND; Caricasole A
    Gene; 1995 Dec; 167(1-2):239-43. PubMed ID: 8566784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of insulin-like growth factor I receptor promoter activity by wild-type and mutant versions of the WT1 tumor suppressor.
    Tajinda K; Carroll J; Roberts CT
    Endocrinology; 1999 Oct; 140(10):4713-24. PubMed ID: 10499530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Egr-1 mediates transcriptional activation of IGF-II gene in response to hypoxia.
    Bae SK; Bae MH; Ahn MY; Son MJ; Lee YM; Bae MK; Lee OH; Park BC; Kim KW
    Cancer Res; 1999 Dec; 59(23):5989-94. PubMed ID: 10606246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1.
    Drummond IA; Madden SL; Rohwer-Nutter P; Bell GI; Sukhatme VP; Rauscher FJ
    Science; 1992 Jul; 257(5070):674-8. PubMed ID: 1323141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High affinity binding sites for the Wilms' tumour suppressor protein WT1.
    Hamilton TB; Barilla KC; Romaniuk PJ
    Nucleic Acids Res; 1995 Jan; 23(2):277-84. PubMed ID: 7862533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of protein phosphatases activates P4 promoter of the human insulin-like growth factor II gene through the specific promoter element.
    Hyun SW; Park K; Lee YS; Lee YI; Kim SJ
    J Biol Chem; 1994 Jan; 269(1):364-8. PubMed ID: 8276819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
    Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG
    Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proto-oncogene N-myc promoter is down regulated by the Wilms' tumor suppressor gene WT1.
    Zhang X; Xing G; Saunders GF
    Anticancer Res; 1999; 19(3A):1641-8. PubMed ID: 10470095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1.
    Cook DM; Hinkes MT; Bernfield M; Rauscher FJ
    Oncogene; 1996 Oct; 13(8):1789-99. PubMed ID: 8895526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A structure-function analysis of transcriptional repression mediated by the WT1, Wilms' tumor suppressor protein.
    Madden SL; Cook DM; Rauscher FJ
    Oncogene; 1993 Jul; 8(7):1713-20. PubMed ID: 8510918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional repression mediated by the WT1 Wilms tumor gene product.
    Madden SL; Cook DM; Morris JF; Gashler A; Sukhatme VP; Rauscher FJ
    Science; 1991 Sep; 253(5027):1550-3. PubMed ID: 1654597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site.
    Werner H; Rauscher FJ; Sukhatme VP; Drummond IA; Roberts CT; LeRoith D
    J Biol Chem; 1994 Apr; 269(17):12577-82. PubMed ID: 8175666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter.
    McCoy C; McGee SB; Cornwell MM
    Cell Growth Differ; 1999 Jun; 10(6):377-86. PubMed ID: 10392899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA binding by the Wilms tumor suppressor zinc finger proteins.
    Caricasole A; Duarte A; Larsson SH; Hastie ND; Little M; Holmes G; Todorov I; Ward A
    Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7562-6. PubMed ID: 8755514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of insulin-like growth factor I receptor gene expression by the Wilms' tumor suppressor WT1.
    Werner H; Roberts CT; Rauscher FJ; LeRoith D
    J Mol Neurosci; 1996; 7(2):111-23. PubMed ID: 8873895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wilms' tumour-suppressor protein isoforms have opposite effects on Igf2 expression in primary embryonic cells, independently of p53 genotype.
    Duarte A; Caricasole A; Graham CF; Ward A
    Br J Cancer; 1998; 77(2):253-9. PubMed ID: 9460996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways.
    Wang ZY; Qiu QQ; Huang J; Gurrieri M; Deuel TF
    Oncogene; 1995 Feb; 10(3):415-22. PubMed ID: 7845666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.